Metaphore possesses a next-generation platform that enhances drug discovery utilising AI technology

Metaphore拥有一个利用人工智能技术增强药物发现的下一代平台。

image credit- shutterstock

图片来源：shutterstock

Japan-based TOHO HOLDINGS has invested in US-based Metaphore Biotechnologies, Inc. through the CVC Fund 'TOHO Ventures'.

总部位于日本的东宝控股通过CVC基金“东宝创投”投资了美国的Metaphore生物技术公司。

Metaphore is a next-generation antibody drug discovery company founded by Flagship Pioneering in the US. Metaphore’s proprietary AI drug discovery platform, “MIMICTM,” distinguishes itself from traditional structure- dependent approaches by designing antibodies starting from biological “functions.”

Metaphore是一家由美国Flagship Pioneering创立的下一代抗体药物发现公司。Metaphore专有的AI药物发现平台“MIMICTM”通过从生物学“功能”出发设计抗体，区别于传统的依赖结构的方法。

The platform performs integrated AI analysis of large-scale functional data obtained from live cells alongside dynamic protein interaction information. This unique approach enables the creation of agonist and multi-functional antibodies, which have historically been difficult to design using structural data alone..

该平台对从活细胞中获得的大规模功能数据与动态蛋白质相互作用信息进行综合人工智能分析。这种独特的方法使得设计过去仅靠结构数据难以实现的激动剂和多功能抗体成为可能。

With its core strengths in molecular optimisation speed and high- potency design capabilities, Metaphore is currently advancing a pipeline with multiple programs in disease areas with high unmet medical needs, aiming to create the next generation of antibody therapeutics.

凭借其在分子优化速度和高效设计能力方面的核心优势，Metaphore 正在推进一条包含多个项目的研发管线，针对具有高度未满足医疗需求的疾病领域，旨在创造下一代抗体疗法。

The Fund primarily invests in advanced overseas startups, focusing on drug discovery and biotechnology sectors and digital health transformation. It will focus on supporting next-generation platforms that dramatically enhance drug discovery productivity through technological innovations in AI, data science, and cellular and genetic engineering, as well as new modalities enabling fundamental disease treatment..

该基金主要投资于海外前沿的初创公司，聚焦药物发现和生物技术领域以及数字健康转型。它将专注于支持下一代通过人工智能、数据科学及细胞和基因工程技术创新极大提高药物研发生产力的技术平台，以及能够实现根本性疾病治疗的新型治疗模式。

Furthermore, the Fund will actively leverage TOHO HOLDINGS’ assets, including its pharmaceutical distribution network, dispensing pharmacy channels, and manufacturing and data infrastructure, to operate as a collaborative CVC that facilitates the commercialization and societal implementation of portfolio companies’ businesses..

此外，该基金将积极利用东邦控股集团的资产，包括其药品分销网络、配药渠道以及制造和数据基础设施，作为协同企业风险投资（CVC），推动投资组合公司的业务商业化和社会实施。